Literature DB >> 12586128

Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication.

Masahiro Yasaka1, Toshiyuki Sakata, Kazuo Minematsu, Hiroaki Naritomi.   

Abstract

We investigated the effect of prothrombin complex concentrate (PCC, median 500 IU) and vitamin K (10-20 mg) or either on blood coagulation and clinical findings in 17 patients with major hemorrhagic complication during warfarin treatment. Their international normalized ratio (INR) at admission was median 2.7 (2.0-above 10.0). In 11 patients treated with PCC and vitamin K, INR decreased to median 1.13 (0.91-1.36) 10 min after the administration with elevation of plasma levels of coagulant factors II, VII, IX, X and protein C.INR decreased abruptly after the administration of PCC without vitamin K in two patients but it increased again 12-24 h after, with decrease of coagulant factors levels. In one of them, a hematoma of the brain enlarged with INR re-increase 12-24 h after the administration. In four patients treated with vitamin K alone, INR decreased slowly from 2.69 (1.03-3.35) to 1.28 (1.25-1.44) 12-24 h after the administration in parallel with gradual increase of the coagulant factors.PCC administration with or without vitamin K seems to be more effective in rapidly correcting increased INR levels than vitamin K treatment without PCC. PCC without vitamin K may result in re-increase of INR and clinical deterioration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12586128     DOI: 10.1016/s0049-3848(02)00402-4

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  41 in total

Review 1.  Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.

Authors:  Andrea Lee; Mark Crowther
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

Review 2.  [Avoiding emergency situations under anticoagulant therapy with vitamin K antagonists].

Authors:  C E Dempfle; M Borggrefe
Journal:  Internist (Berl)       Date:  2005-09       Impact factor: 0.743

3.  Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding.

Authors:  D Imberti; A Magnacavallo; F Dentali; E Condoleo; M Gallerani; R Benedetti; W Ageno
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

Review 4.  Fixed-dose 4-factor prothrombin complex concentrate: we don't know where we're going if we don't know how to get there.

Authors:  Scott T Hall; Kyle C Molina
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

Review 5.  Therapies for Hemorrhagic Transformation in Acute Ischemic Stroke.

Authors:  Joshua A Stone; Joshua Z Willey; Salah Keyrouz; James Butera; Ryan A McTaggart; Shawna Cutting; Brian Silver; Bradford Thompson; Karen L Furie; Shadi Yaghi
Journal:  Curr Treat Options Neurol       Date:  2017-01       Impact factor: 3.598

6.  Intracerebral hemorrhage: clinical overview and pathophysiologic concepts.

Authors:  Fred Rincon; Stephan A Mayer
Journal:  Transl Stroke Res       Date:  2012-04-21       Impact factor: 6.829

Review 7.  [Bleeding risk and perioperative management of patients anticoagulated with vitamin K antagnosists].

Authors:  Marzia Angelo; Ingrid Stockner; Christian J Wiedermann
Journal:  Wien Med Wochenschr       Date:  2008

8.  Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy.

Authors:  Cezary Wójcik; Michelle L Schymik; Eric G Cure
Journal:  Int J Emerg Med       Date:  2009-11-26

9.  Current treatment options for intracerebral hemorrhage.

Authors:  Fred Rincon; Stephan A Mayer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-06

Review 10.  Clinical review: Critical care management of spontaneous intracerebral hemorrhage.

Authors:  Fred Rincon; Stephan A Mayer
Journal:  Crit Care       Date:  2008-12-10       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.